If you made any changes in Pure these will be visible here soon.

Research Output 1991 2019

  • 5727 Citations
  • 31 h-Index
  • 128 Article
  • 2 Review article
Filter
Article
2016
94 Citations (Scopus)

Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation

Mohty, M., Malard, F., Abecassis, M., Aerts, E., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Bazarbachi, A., Blaise, D., Ciceri, F., Corbacioglu, S., Dalle, J. H., Dignan, F., Fukuda, T., Huynh, A., Masszi, T., Michallet, M., Nagler, A. & 12 others, NiChonghaile, M., Okamoto, S., Pagliuca, A., Peters, C., Petersen, F. B., Richardson, P. G., Ruutu, T., Savani, B. N., Wallhult, E., Yakoub-Agha, I., Duarte, R. F. & Carreras, E., máj. 16 2016, (Accepted/In press) In : Bone Marrow Transplantation.

Research output: Article

Hepatic Veno-Occlusive Disease
Transplantation
Bone Marrow
Cell Transplantation
Bone Marrow Transplantation
71 Citations (Scopus)

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

Verstovsek, S., Vannucchi, A. M., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Kirito, K., Besses, C., Hino, M., Moiraghi, B., Miller, C. B., Cazzola, M., Rosti, V., Blau, I., Mesa, R., Jones, M. M., Zhen, H. & 4 others, Li, J., Francillard, N., Habr, D. & Kiladjian, J. J., 2016, In : Haematologica. 101, 7, p. 821-829 9 p.

Research output: Article

Polycythemia Vera
Spleen
Therapeutics
Hydroxyurea
Hematocrit
2017
22 Citations (Scopus)

Carfilzomib-lenalidomide-dexamethasone vs lenalidomide- dexamethasone in relapsed multiple myeloma by previous treatment

Dimopoulos, M. A., Stewart, A. K., Masszi, T., Spicka, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D., Mihaylov, G. G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A., San-Miguel, J., Ludwig, H., Ro, S., Aggarwal, S., Moreau, P. & Palumbo, A., jan. 1 2017, In : Blood Cancer Journal. 7, 4, e554.

Research output: Article

Multiple Myeloma
Dexamethasone
Thalidomide
Disease-Free Survival
Therapeutics
1 Citation (Scopus)

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide

Harrison, C. N., Griesshammer, M., Miller, C., Masszi, T., Passamonti, F., Zachee, P., Durrant, S., Pane, F., Guglielmelli, P., Verstovsek, S., Jones, M. M., Hunter, D. S., Sun, W., Li, J., Khan, M., Habr, D. & Kiladjian, J. J., jan. 1 2017, (Accepted/In press) In : British Journal of Haematology.

Research output: Article

Polycythemia Vera
INCB018424
19 Citations (Scopus)

Impact of prior therapy on the efficacy and safety of oral ixazomiblenalidomide-dexamethasone vs. Placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

Mateos, M. V., Masszi, T., Grzasko, N., Hansson, M., Sandhu, I., Pour, L., Viterbo, L., Jackson, S. R., Stoppa, A. M., Gimsing, P., Hamadani, M., Borsaru, G., Berg, D., Lin, J., Di Bacco, A., Van De Velde, H., Richardson, P. G. & Moreau, P., szept. 30 2017, In : Haematologica. 102, 10, p. 1767-1775 9 p.

Research output: Article

Multiple Myeloma
Dexamethasone
Placebos
Safety
Therapeutics
31 Citations (Scopus)

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

Avet-Loiseau, H., Bahlis, N. J., Chng, W. J., Masszi, T., Viterbo, L., Pour, L., Ganly, P., Palumbo, A., Cavo, M., Langer, C., Pluta, A., Nagler, A., Kumar, S., Ben-Yehuda, D., Rajkumar, S. V., San-Miguel, J., Berg, D., Lin, J., Van De Velde, H., Esseltine, D. L. & 3 others, di Bacco, A., Moreau, P. & Richardson, P. G., dec. 14 2017, In : Blood. 130, 24, p. 2610-2618 9 p.

Research output: Article

Refractory materials
Disease-Free Survival
Chromosome Aberrations
Placebos
Hazards
27 Citations (Scopus)

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

Kumar, S., Moreau, P., Hari, P., Mateos, M. V., Ludwig, H., Shustik, C., Masszi, T., Spencer, A., Hájek, R., Romeril, K., Avivi, I., Liberati, A. M., Minnema, M. C., Einsele, H., Lonial, S., Berg, D., Lin, J., Gupta, N., Esseltine, D. L. & Richardson, P. G., aug. 1 2017, In : British Journal of Haematology. 178, 4, p. 571-582 12 p.

Research output: Article

Multiple Myeloma
Dexamethasone
Placebos
Thrombocytopenia
Proteasome Inhibitors
1 Citation (Scopus)

Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma

Varga, G., Mikala, G., Kiss, K. P., Kosóczki, É., Szabó, E., Meggyesi, N., Balassa, K., Kövy, P., Tegze, B., Szombath, G., Tordai, A., Andrikovics, H., Homolya, L. & Masszi, T., nov. 1 2017, In : Clinical Lymphoma, Myeloma and Leukemia. 17, 11, p. 734-742 9 p.

Research output: Article

Proteasome Endopeptidase Complex
Multiple Myeloma
Alleles
Disease-Free Survival
Genotype
2018
7 Citations (Scopus)

Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT

Giebel, S., Labopin, M., Potter, M., Poiré, X., Sengeloev, H., Socié, G., Huynh, A., Afanasyev, B. V., Schanz, U., Ringden, O., Kalhs, P., Beelen, D. W., Campos, A. M., Masszi, T., Canaani, J., Mohty, M. & Nagler, A., jún. 1 2018, In : European Journal of Cancer. 96, p. 73-81 9 p.

Research output: Article

Hematopoietic Stem Cell Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Unrelated Donors
Leukemia
Tissue Donors
30 Citations (Scopus)

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

Ross, D. M., Masszi, T., Gómez Casares, M. T., Hellmann, A., Stentoft, J., Conneally, E., Garcia-Gutierrez, V., Gattermann, N., Le Coutre, P. D., Martino, B., Saussele, S., Giles, F. J., Radich, J. P., Saglio, G., Deng, W., Krunic, N., Bédoucha, V., Gopalakrishna, P. & Hochhaus, A., febr. 22 2018, (Accepted/In press) In : Journal of Cancer Research and Clinical Oncology. p. 1-10 10 p.

Research output: Article

Leukemia, Myeloid, Chronic Phase
Therapeutics
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Disease Progression
5 Citations (Scopus)

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies

Kiladjian, J. J., Guglielmelli, P., Griesshammer, M., Saydam, G., Masszi, T., Durrant, S., Passamonti, F., Jones, M., Zhen, H., Li, J., Gadbaw, B., Perez Ronco, J., Khan, M. & Verstovsek, S., ápr. 1 2018, In : Annals of Hematology. 97, 4, p. 617-627 11 p.

Research output: Article

Interferons
Safety
Hydroxyurea
Polycythemia Vera
Phlebotomy
2 Citations (Scopus)

Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study)

Schneider, T., Rosta, A., Losonczy, H., Radványi, G., Ujj, G., Egyed, M., Illés, A., Jakucs, J., Szerafin, L., Gasztonyi, Z., Masszi, T., Iványi, J., Demeter, J., Dombi, P., Tóth, A. & Borbényi, Z., ápr. 1 2018, In : Pathology and Oncology Research. 24, 2, p. 199-205 7 p.

Research output: Article

Follicular Lymphoma
Disease-Free Survival
Therapeutics
Survival
Controlled Clinical Trials
17 Citations (Scopus)

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Moskowitz, C. H., Walewski, J., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Viviani, S., Bachanova, V., Sureda, A., McClendon, T., Lee, C., Lisano, J. & Sweetenham, J., dec. 20 2018, In : Blood. 132, 25, p. 2639-2642 4 p.

Research output: Article

Hodgkin Disease
Disease-Free Survival
Recurrence
Placebos
Confidence Intervals
5 Citations (Scopus)

High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party

Akhtar, S., Montoto, S., Boumendil, A., Finel, H., Masszi, T., Jindra, P., Nemet, D., Fuhrmann, S., Beguin, Y., Castagna, L., Ferrara, F., Capria, S., Malladi, R., Moraleda, J. M., Bloor, A., Ghesquières, H., Meissner, J., Sureda, A. & Dreger, P., jan. 1 2018, In : American Journal of Hematology. 93, 1, p. 40-46 7 p.

Research output: Article

Stem Cell Transplantation
Hodgkin Disease
Lymphoma
Retrospective Studies
Transplantation
9 Citations (Scopus)

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the chronic malignancies working party of the EBMT

Gagelmann, N., Eikema, D. J., Iacobelli, S., Koster, L., Nahi, H., Stoppa, A. M., Masszi, T., Caillot, D., Lenhoff, S., Udvardy, M., Crawley, C., Arcese, W., Mariette, C., Hunter, A., Leleu, X., Schipperus, M., Delforge, M., Pioltelli, P., Snowden, J. A., Itälä-Remes, M. & 4 others, Musso, M., van Biezen, A., Garderet, L. & Kröger, N., ápr. 30 2018, In : Haematologica. 103, 5, p. 890-897 8 p.

Research output: Article

Stem Cell Transplantation
Multiple Myeloma
Neoplasms
Transplantation
Survival
15 Citations (Scopus)

Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

Leleu, X., Masszi, T., Bahlis, N. J., Viterbo, L., Baker, B., Gimsing, P., Maisnar, V., Samoilova, O., Rosiñol, L., Langer, C., Song, K., Izumi, T., Cleeland, C., Berg, D., Lin, H. M., Zhu, Y., Skacel, T., Moreau, P. & Richardson, P. G., aug. 1 2018, In : American Journal of Hematology. 93, 8, p. 985-993 9 p.

Research output: Article

Multiple Myeloma
Dexamethasone
Placebos
Quality of Life
Therapeutics

Sex-specific survival difference in association with HLA-DRB1∗04 following allogeneic haematopoietic stem cell transplantation for lymphoid malignancies

Balassa, K., Andrikovics, H., Remenyi, P., Batai, A., Szilvasi, A., Bors, A., Kiss, K. P., Rajczy, K., Inotai, D., Torbagyi, E., Lengyel, L., Barta, A., Gopcsa, L., Tordai, A. & Masszi, T., jan. 1 2018, In : Human Immunology. 79, 1, p. 13-19 7 p.

Research output: Article

Hematopoietic Stem Cell Transplantation
Tissue Donors
Survival
Neoplasms
Transplantation

Skin-homing CD8+ T cells preferentially express GPI-anchored peptidase inhibitor 16, an inhibitor of cathepsin K

Lupsa, N., Érsek, B., Horváth, A., Bencsik, A., Lajkó, E., Silló, P., Oszvald, Á., Wiener, Z., Reményi, P., Mikala, G., Masszi, T., Búzás, E. & Pós, Z., dec. 1 2018, In : European Journal of Immunology. 48, 12, p. 1944-1957 14 p.

Research output: Article

Cathepsin K
Protease Inhibitors
Skin
Graft vs Host Disease
Granzymes

The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma

Kiss, K. P., Varga, G., Mikala, G., Balassa, K., Bors, A., Kovy, P., Meggyesi, N., Kozma, A., Csacsovszki, O., Remenyi, P., Valyi-Nagy, I., Tordai, A., Masszi, T. & Andrikovics, H., márc. 4 2018, In : Leukemia and Lymphoma. 59, 3, p. 710-716 7 p.

Research output: Article

Clinical Protocols
Multiple Myeloma
Oncogenes
Proteasome Inhibitors
Genes
2019
1 Citation (Scopus)

Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor

Sureda, A., Chabannon, C., Masszi, T., Pohlreich, D., Scheid, C., Thieblemont, C., Wahlin, B. E., Sakellari, I., Russell, N., Janikova, A., Dabrowska-Iwanicka, A., Touzeau, C., Esquirol, A., Jantunen, E., van der Werf, S., Bosman, P., Boumendil, A., Liu, Q., Celanovic, M., Montoto, S. & 1 others, Dreger, P., jan. 1 2019, (Accepted/In press) In : Bone Marrow Transplantation.

Research output: Article

Granulocyte Colony-Stimulating Factor
Registries
Lymphoma
Transplantation
Bone Marrow
1 Citation (Scopus)

Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms

Mózes, R., Gángó, A., Sulák, A., Vida, L., Reiniger, L., Timár, B., Krenács, T., Alizadeh, H., Masszi, T., Gaál-Weisinger, J., Demeter, J., Csomor, J., Matolcsy, A., Kajtár, B. & Bödör, C., jan. 1 2019, (Accepted/In press) In : Pathology.

Research output: Article

Calreticulin
Immunohistochemistry
Mutation
Neoplasms
Essential Thrombocythemia
2 Citations (Scopus)

Donor KIR2DS1 reduces the risk of transplant related mortality in HLA-C2 positive young recipients with hematological malignancies treated by myeloablative conditioning

Tordai, A., Bors, A., Kiss, K. P., Balassa, K., Andrikovics, H., Batai, A., Szilvasi, A., Rajczy, K., Inotai, D., Torbagyi, E., Lengyel, L., Barta, A., Remenyi, P. & Masszi, T., jan. 1 2019, In : PloS one. 14, 6, e0218945.

Research output: Article

Open Access
Transplants
Hematologic Neoplasms
Stem cells
cell transplantation
Tissue Donors
Graft vs Host Disease
Steroids
Therapeutics
Inferior Mesenteric Artery
Superior Mesenteric Artery

Identification of the best-suited donor for generating virus-specific T cells

Tasnády, S., Karászi, É., Szederjesi, A., Bihari, G., Juhász, Z., Hardi, A., Kriván, G., Kállay, K., Reményi, P., Sinkó, J., Mikala, G., Réti, M. & Masszi, T., jan. 1 2019, (Accepted/In press) In : Vox sanguinis.

Research output: Article

Donor Selection
Tissue Donors
Viruses
T-Lymphocytes
Leukapheresis
1 Citation (Scopus)

Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia

on behalf of the Chronic Malignancies Working Party of the European Society for Blood Marrow Transplantation, jan. 1 2019, In : British Journal of Haematology.

Research output: Article

Stem Cell Transplantation
Acute Myeloid Leukemia
Leukemia
Leukemia, Myelomonocytic, Chronic
Myelodysplastic Syndromes

Investigation of TGFB1 −1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation

Kövy, P., Meggyesi, N., Varga, L., Balassa, K., Bors, A., Gopcsa, L., Paksi, M., Bátai, Á., Vad, E., Sinkó, J., Tordai, A., Masszi, T., Reményi, P. & Andrikovics, H., jan. 1 2019, (Accepted/In press) In : Bone Marrow Transplantation.

Research output: Article

Hematopoietic Stem Cell Transplantation
Graft vs Host Disease
Biomarkers
Transplantation Conditioning
Transforming Growth Factors

Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients

Lovas, S., Varga, G., Farkas, P., Masszi, T., Wohner, N., Bereczki, Á., Adamkovich, N., Borbényi, Z., Szomor, Á., Alizadeh, H., Szaleczky, E., Wolf, K., Schneider, T., Plander, M., Szendrei, T., Csacsovszki, O., Csukly, Z., Rajnics, P., Egyed, M., Nagy, Z. & 4 others, Rejtő, L., Illés, A., Mikala, G. & Váróczy, L., jan. 1 2019, In : International Journal of Hematology.

Research output: Article

Multiple Myeloma
Safety
Disease-Free Survival
Kidney
Therapeutics
1 Citation (Scopus)

Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

Morris, C., Chabannon, C., Masszi, T., Russell, N., Nahi, H., Kobbe, G., Krejci, M., Auner, H. W., Pohlreich, D., Hayden, P., Basak, G. W., Lenhoff, S., Schaap, N., van Biezen, A., Knol, C., Iacobelli, S., Liu, Q., Celanovic, M., Garderet, L. & Kröger, N., jan. 1 2019, (Accepted/In press) In : Bone Marrow Transplantation.

Research output: Article

Open Access
Hematopoietic Stem Cell Mobilization
Granulocyte Colony-Stimulating Factor
Multiple Myeloma
Registries
Disease-Free Survival